Any thoughts that initial public offerings (IPOs) for biotech companies have run out of steam will have to change those ideas. Wall Street is certainly warming up to biotech IPOs once again. Following this week's IPO pricing and strong market debut by ZS Pharma Inc., Fremont, Calif.-based Ardelyx Inc. followed suit, taking advantage of that renewed enthusiasm from investors and raised $60 million.